Comparative Pharmacology
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROGEL.
METRO I.V. IN PLASTIC CONTAINER vs METROGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
None Documented
None Documented
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)